We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > TREMFYA

News List

Janssen launches PhII/III programme testing Tremfya in Crohn’s pharmatimes
July 12, 2018
Janssen has kicked off a Phase II/III programme assessing Tremfya in Crohn's Disease.
Janssen's Tremfya gets go-ahead from NICE in plaque psoriasis pharmafile
May 15, 2018
NICE, the UK’s drug watchdog for the NHS, has decided that Janssen’s Tremfya (guselkumab) should be used routinely through the health service in the treatment of plaque psoriasis, having judged it an efficient use of financial resources.
Janssen’s Tremfya backed for NHS use pharmatimes
May 15, 2018
Janssen’s Tremfya has been recommended by NICE as a cost-effective treatment for plaque psoriasis.
New Data Shows TREMFYA Improved Psoriatic Arthritis Symptoms through One Year americanpharmaceuticacreview
November 08, 2017
Janssen announced longer-term results from a Phase 2 study investigating TREMFYA (guselkumab), the first selective anti-interleukin (IL)-23 monoclonal antibody to show positive results in the treatment of active psoriatic arthritis.

Previous page 1 2 3 Next page